Trial Profile

A Phase 1/2, Open-Label, Multi-Center Study of ZN-c3 Administered in Combination with Encorafenib and Cetuximab in Adults with Metastatic Colorectal Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 04 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Azenosertib (Primary) ; Cetuximab (Primary) ; Encorafenib (Primary)
Indications Adenocarcinoma; Colorectal cancer
Focus Adverse reactions; Therapeutic Use
Sponsors K-Group Beta

Most Recent Events

25 Mar 2025 According to a Zentalis Pharmaceuticals media release, the company will present data from this study at the 2025 American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30, 2025, in Chicago, IL.
29 Jan 2025 Results published in the Zentalis Pharmaceuticals media release.
26 Nov 2024 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com